Advertisement

Management of neurosarcoidosis

Published:September 15, 2022DOI:https://doi.org/10.1016/j.jneuroim.2022.577958

      Highlights

      • This paper summarises the therapeutic and rehabilitative management in neurosarcoidosis.
      • The drugs used and their monitoring are noted
      • Treatment guidelines for individual clinical subtypes of the disorder are provided
      • The importance of rehabilitative measures and lifestyle changes are emphasised

      Abstract

      This is a brief and purposefully practical approach to the therapeutic and rehabilitative management of patients affected by neurological complications of systemic sarcoidosis.
      The review notes the drugs used and their monitoring, and their role in the series of clinical subgroups identified to form the condition. Treatment guidelines for individual clinical subtypes of the disorder are provided, and the importance of rehabilitative measures and lifestyle changes are emphasised.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bathla G.
        • Dandapt S.
        • Soni N.
        • Maheshwarappa R.P.
        Neuroimaging findings in intracranial sarcoid phlebitis: a case report.
        J. Stroke Cerebrovasc. Dis. 2019; 28: 369-370
        • Bathla G.
        • Abdel-Wahed L.
        • Agarwal A.
        • et al.
        Vascular involvement in neurosarcoidosis: early experience from intracranial vessel wall imaging.
        Neurol. Neuroimmunol. Neuroinflammation. 2021; 8e1063
        • Baughman R.P.
        • Lower E.E.
        Treatment of sarcoidosis.
        Clin. Rev. Allergy Immunol. 2015; 49: 79-92
        • Baughman R.P.
        • Valeyre D.
        • Korsten P.
        • et al.
        ERS clinical practice guidelines on treatment of sarcoidosis.
        Eur. Respir. J. 2021; 58: 2004079
        • Bitoun S.
        • Bouvry D.
        • Borie R.
        • et al.
        Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil.
        Neurology. 2016; 87: 1-5
        • Bomprezzi R.
        • Pati S.
        • Chansakul C.
        • Vollmer T.
        A case of neurosarcoidosis successfully treated with rituximab.
        Neurology. 2010; 75: 568-570
        • Cohen-Aubart F.
        • Bouvry D.
        • Galanaud D.
        • et al.
        Long-term outcomes of refractory neurosarcoidosis treated with infliximab.
        J. Neurol. 2017; 264: 891-897
        • Cohen-Aubart F.
        • Abbara S.
        • Maisonobe T.
        • et al.
        Symptomatic muscular sarcoidosis: lesson from a nationwide multicentre study.
        Neurol. Neuroinflamm. Neuroimmunol. 2018; e452
        • Crommelin H.A.
        • van der Burg L.M.
        • Vorselaars A.D.M.
        • et al.
        Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
        Respir. Med. 2016; 115: 72-77
        • Damsky W.
        • Thakral D.
        • Emeagwali N.
        • Galan A.
        • King B.
        Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis.
        N. Engl. J. Med. 2018; 379: 2540-2546
        • Damsky W.
        • Young B.D.
        • Sloan B.
        • Miller E.J.
        • Obando J.A.
        • King B.
        Treatment of multiorgan sarcoidosis with tofacitinib.
        ARC Open Rheumatol. 2020; 3: 106-109
        • Drent M.
        • Cremers J.P.
        • Jansen T.L.
        • Baughman R.P.
        Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis.
        Sarc. Vasc. Diffuse Lung. Dis. 2014; 31: 91-107
        • Earle B.
        • Wolf D.S.
        • Ramsay E.S.
        Novel use of rituximab in treatment refractory neurosarcoidosis in an 11 year old girl.
        J. Clin. Rheumatol. 2019; 25: e101-e103
        • Fritz D.
        • Timmermans W.M.C.
        • van Laar J.A.M.
        • et al.
        Infliximab treatment in pathology-confirmed neurosarcoidosis.
        Neurol. Neuroimmunol. Neuroinflammation. 2020; 7e847
        • Gelfand J.M.
        • Bradshaw M.J.
        • Stern B.J.
        • et al.
        Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series.
        Neurology. 2017; 89: 2092-2100
        • Grunewald J.
        • Grutters J.C.
        • Arkema E.V.
        • Saketkoo L.A.
        • Moller D.R.
        • Muller-Quernheim J.
        Sarcoidosis.
        Natl. Rev. 2019; 5: 45
        • Heaney D.
        • Geddes J.F.
        • Nagendran K.
        • Swash M.
        Sarcoid polyneuropathy responsive to intravenous immunoglobulin.
        Muscle Nerve. 2004; 29: 447-450
        • Herring A.B.
        • Urich H.
        Sarcoidosis of the central nervous system.
        J. Neurol. Sci. 1969; 9: 405-422
        • Hutto S.K.
        • Kyle K.
        • Cavanagh J.J.
        • Reda H.
        • Venna N.
        Adalimumab for CNS sarcoidosis: single center experience and review.
        J. Neurol. 2022; 269: 2064-2072
        • James W.E.
        • Baughman R.
        Treatment of sarcoidosis: grading the evidence.
        Expert. Rev. Clin. Pharmacol. 2018; https://doi.org/10.1080/17512433.2018.1486706
        • Jamilloux Y.
        • Cohen-Aubart F.
        • Chapelon-Abric C.
        • et al.
        Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicentre study of 132 patients.
        Semin. Arthritis Rheum. 2018; 47: 288-294
        • Joubert B.
        • Chapelon-Abric C.
        • Biard L.
        • et al.
        Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis.
        JAMA Neurol. 2017; 74: 1336-1344
        • Judson M.A.
        • Costabel U.
        • Drent M.
        • et al.
        The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool.
        Sarc. Vasc. Diffuse Lung. Dis. 2014; 31: 19-27
        • Kidd D.P.
        Sarcoidosis of the central nervous system: clinical features, imaging and CSF results.
        J. Neurol. 2018; 265: 1906-1915
        • Kidd D.P.
        Neurosarcoidosis: a review of the clinical manifestations, investigation results and treatment.
        Pract. Neurol. 2020; 20: 199-212
        • Kidd D.P.
        Sarcoidosis of the central nervous system: safety and efficacy of treatment, and experience of biological therapies.
        Clin. Neurol. Neurosurg. 2020; 194 (Mar 20): 105811
        • Kidd D.P.
        • McCabe D.J.
        • Wilhelm T.
        • Galloway M.
        Carotid arteritis causing amaurosis fugax and ischaemic cerebrovascular events in neurosarcoidosis.
        Clin. Neurol. Neurosurg. 2018; 169: 103-106
        • Kidd D.P.
        • Galloway M.
        • Wilhelm T.
        Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar.
        Neurology. 2020; 94: 991-993
        • Ko J.K.
        • Lee S.W.
        • Choi C.H.
        Moyamoya-like vasculopathy in Neurosarcoidosis.
        J. Korean Neurosurg. Soc. 2009; 45: 50-52
        • Le Roux K.
        • Streichenberger N.
        • Vial C.
        • et al.
        Granulomatous myositis: a clinical study of thirteen cases.
        Muscle Nerve. 2007; 35: 171-177
        • Marnane M.
        • Lynch T.
        • Scott J.
        • Stack J.
        • Kelly P.J.
        Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab.
        J. Neurol. 2009; 256: 139-140
        • Morton-Holtham L.
        • Swann N.
        • Brewer J.
        • Moir H.J.
        A systemic review of physical activity and physical fitness in sarcoidosis.
        TSM. 2021; 4: 741-755
        • O’Dwyer J.P.
        • Al-Moyeed B.A.
        • Farrell M.A.
        • et al.
        Neurosarcoidosis-related intracranial haemorrhage: three new cases and a systematic review of the literature.
        Eur. J. Neurol. 2013; 20: 71-78
        • Panselinas E.
        • Rodgers J.K.
        • Judson M.A.
        Clinical outcomes in sarcoidosis after cessation of infliximab treatment.
        Respirology. 2009; 14: 522-528
        • Riller Q.
        • Cotteret C.
        • Junot H.
        • et al.
        Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.
        J. Neurol. 2019; 266: 1073-1078
        • Rudski J.D.
        Risk of cancer after long-term therapy of auto-immune disorders with glucocorticoids and DMARDs – a controversial issue.
        Memo. 2019; 12: 225-229
        • Said G.
        Sarcoidosis of the peripheral nervous system.
        Handb. Clin. Neurol. 2013; 115: 485-495
        • Saketkoo L.A.
        • Baughman R.P.
        Biologic therapies in the treatment of sarcoidosis.
        Expert. Rev. Clin. Immunol. 2016; 12: 817-825
        • Sharp M.
        • Donnelly S.C.
        • Moller D.R.
        Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents.
        Respir. Med. J. 2019; 1100004
        • Tavee J.O.
        • Karwa K.
        • Ahmed Z.
        • Thompson N.
        • Parambil J.
        • Culver D.A.
        Sarcoidosis-associated small fibre neuropathy in a large cohort: clinical aspects and response to IVIg and anti-TNF alpha treatment.
        Respir. Med. 2017; 126: 135-138
        • Vorselaars A.D.M.
        • Verwoerd A.
        • van Moorsel S.H.M.
        • Keijsers R.G.M.
        • Rijkers G.T.
        • Grutters J.C.
        Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.
        Eur. Respir. J. 2014; 43: 602-609
        • Vukojevic Z.
        • Ilic T.V.
        • Dominovic-Kovacevic A.
        • Grgic S.
        • Mavija S.
        Neurosarcoidosis and multiple intracerebral hematomas: an unusual clinical presentation.
        J. Neurol. Sci. 2017; 379: 22-24
        • Zella S.
        • Kneiphof J.
        • Haghikia A.
        • Gold R.
        • Woitalla Thone J.
        Successful therapy with rituximab in three patients with probable neurosarcoidosis.
        Ther. Adv. Neurol. Disord. 2018; 11 (1756286418805732)